7th Aug 2020 11:39
Okyo Pharma Ltd - London-based biopharmaceutical company - Names James Khodabakhsh as chair of newly-established scientific advisory board. Khodabakhsh will bring together a group of experts to review and inform the company's plans to progress its dry eye treatment Chemerin to an Investigational New Drug application. Khodabakhsh is medical director at the Beverly Hills Institute of Ophthalmology and is also chair of the Department of Ophthalmology at the Cedars Sinai Medical Centre.
Current stock price: 15.74 pence
Year-to-date change: up more than 100%; 1.70p at December 31.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
OKYO.L